TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint
The company reported that its Phase 3 CYPRESS study of ampreloxetine in patients with hypotension failed to meet its primary endpoint.